The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
COVID-19-neutralizing antibodies predict disease severity and survival
Open accessPublished version of a preprint
Abstract
SUMMARY COVID-19 exhibits variable symptom severity ranging from asymptomatic to life-threatening, yet the relationship between severity and the humoral immune response is poorly understood. We examined antibody responses in 113 COVID-19 patients and found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-RBD antibody levels. While anti-RBD IgG levels generally correlated with neutralization titer, quantitation of neutralization potency revealed that high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G, suggesting cross-protection from reinfection by either strain. However, SARS-CoV-2 sera generally lacked cross-neutralization to a highly-homologous pre-emergent bat coronavirus, WIV1-CoV, that has not yet crossed the species barrier. These results highlight the importance of neutralizing humoral immunity on disease progression and the need to develop broadly protective interventions to prevent future coronavirus pandemics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Wynants, L., Van Calster, B., Bonten, M. M., Collins, G. S., Debray, T. P., De Vos, M., Haller, M. C., Heinze, G., Moons, K. G., Riley, R. D., et al. (2020) · doi:10.1101/2020.03.24.20041020 · Cited by 3,070
Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis
Norrander, J., Kempe, T., & Messing, J. (1983) · Gene · doi:10.1016/0378-1119(83)90040-9 · Cited by 2,497
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · cited 2×
“Although non-RBD anti-spike antibodies can cross-react between different coronaviruses (Secchi et al., 2020; Chan et al., 2005; Ju et al., 2020), we assessed for cross-reactivity of antiRBD IgG in sera of SARS-CoV-2 seropositive individuals by modifying our ELISA to detect IgG antibodies against the RBD of SARS-CoV an…”
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Spike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558 · cited 4×
“effect of unknown clinical significance that was seen in prior studies (Korber et al., 2020; Plante et al., 2020).”
InfluentialDevelopment of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,318
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,252
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156
Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020) · BMJ · doi:10.1136/bmj.m1849 · Cited by 1,135
A human monoclonal antibody blocking SARS-CoV-2 infection
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., & Bosch, B.-J. (2020) · Nature Communications · doi:10.1038/s41467-020-16256-y · Cited by 1,132
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T. P., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.032 · Cited by 1,025
Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., Yang, B., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa449 · Cited by 1,020
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997
Self-citationWu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc2241 · Cited by 993
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30173-9 · Cited by 939
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., et al. (2020) · Science · doi:10.1126/science.abe8499 · Cited by 900
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 847
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816
Self-citationExtrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19
Woodruff, M. C., Ramonell, R. P., Nguyen, D. C., Cashman, K. S., Saini, A. S., Haddad, N. S., Ley, A. M., Kyu, S., Howell, J. C., Ozturk, T., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-00814-z · Cited by 791
Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789
Self-citationCrawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 776
Self-citationEstablishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711
C-reactive protein levels in the early stage of COVID-19
Wang, L. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.007 · Cited by 686
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity
Shrock, E., Fujimura, E., Kula, T., Timms, R. T., Lee, I.-H., Leng, Y., Robinson, M. L., Sie, B. M., Li, M. Z., Chen, Y., et al. (2020) · Science · doi:10.1126/science.abd4250 · Cited by 678
Self-citationStadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Kirkpatrick, E., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 649
ter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S. W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 612
Broad neutralization of SARS-related viruses by human monoclonal antibodies
Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D. P., Haslwanter, D., Sakharkar, M., Jangra, R. K., Dieterle, M. E., Lilov, A., Huang, D., et al. (2020) · Science · doi:10.1126/science.abc7424 · Cited by 539
SARS-CoV-2 spike D614G change enhances replication and transmission
Zhou, B., Thao, T. T. N., Hoffmann, D., Taddeo, A., Ebert, N., Labroussaa, F., Pohlmann, A., King, J., Steiner, S., Kelly, J. N., et al. (2021) · Nature · doi:10.1038/s41586-021-03361-1 · Cited by 538
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., An, Y., Cheng, Y., Li, S., Liu, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.035 · Cited by 495
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies
Hassan, A. O., Case, J. B., Winkler, E. S., Thackray, L. B., Kafai, N. M., Bailey, A. L., McCune, B. T., Fox, J. M., Chen, R. E., Alsoussi, W. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.011 · Cited by 494
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., et al. (2020) · Science · doi:10.1126/science.abc5343 · Cited by 440
SARS-like WIV1-CoV poised for human emergence
Menachery, V. D., Yount, B. L., Sims, A. C., Debbink, K., Agnihothram, S. S., Gralinski, L. E., Graham, R. L., Scobey, T., Plante, J. A., Royal, S. R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517719113 · Cited by 418
Meng, Y., Wu, P., Lu, W., Liu, K., Ma, K., Huang, L., Cai, J., Zhang, H., Qin, Y., Sun, H., et al. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008520 · Cited by 343
Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms
Tersalvi, G., Vicenzi, M., Calabretta, D., Biasco, L., Pedrazzini, G., & Winterton, D. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.009 · Cited by 328
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover
Soresina, A., Moratto, D., Chiarini, M., Paolillo, C., Baresi, G., Focà, E., Bezzi, M., Baronio, B., Giacomelli, M., & Badolato, R. (2020) · Pediatric Allergy and Immunology · doi:10.1111/pai.13263 · Cited by 327
Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events
Lemieux, J. E., Siddle, K. J., Shaw, B. M., Loreth, C., Schaffner, S. F., Gladden-Young, A., Adams, G., Fink, T., Tomkins-Tinch, C. H., Krasilnikova, L. A., et al. (2021) · Science · doi:10.1126/science.abe3261 · Cited by 310
Self-citationSong, G., He, W.-T., Callaghan, S., Anzanello, F., Huang, D., Ricketts, J., Torres, J. L., Beutler, N., Peng, L., Vargas, S., et al. (2020) · doi:10.1101/2020.09.22.308965 · Cited by 285 · cited 1×
“The diverse and atypical kinetics of antibody production—in particular, early rise of IgG and in some cases IgA—suggests the possibility of a contribution from class-switched (IgG or IgA) memory B cells early in the humoral immune response rather than solely from the naive (IgM) B cell pool, as has been recently postu…”
Song, G., He, W.-T., Callaghan, S., Anzanello, F., Huang, D., Ricketts, J., Torres, J. L., Beutler, N., Peng, L., Vargas, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23074-3 · Cited by 285
Immunogenicity and protective efficacy of influenza vaccination
Hannoun, C., Megas, F., & Piercy, J. (2004) · Virus Research · doi:10.1016/j.virusres.2004.02.025 · Cited by 260
Moore, M. J., Dorfman, T., Li, W., Wong, S. K., Li, Y., Kuhn, J. H., Coderre, J., Vasilieva, N., Han, Z., Greenough, T. C., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10628-10635.2004 · Cited by 243
Kopf, M., Herren, S., Wiles, M. V., Pepys, M. B., & Kosco-Vilbois, M. H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.10.1895 · Cited by 196
Case, J. B., Rothlauf, P. W., Chen, R. E., Kafai, N. M., Fox, J. M., Smith, B. K., Shrihari, S., McCune, B. T., Harvey, I. B., Keeler, S. P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.018 · Cited by 192
McBride, C. E., Li, J., & Machamer, C. E. (2007) · Journal of Virology · doi:10.1128/jvi.02146-06 · Cited by 182
The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)
Domingo, P., Mur, I., Pomar, V., Corominas, H., Casademont, J., & Benito, N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102887 · Cited by 174
Prevalence of Antibodies to Four Human Coronaviruses Is Lower in Nasal Secretions than in Serum
Gorse, G. J., Patel, G. B., Vitale, J. N., & O'Connor, T. Z. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00278-10 · Cited by 165
Lontok, E., Corse, E., & Machamer, C. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5913-5922.2004 · Cited by 152
Dynamics and significance of the antibody response to SARS-CoV-2 infectionPreprint
Iyer, A., Jones, F. K., Nodoushani, A., Kelly, M., Becker, M. V., Slater, D., Mills, R., Teng, E., Kamruzzaman, M., Garcia-Beltran, W., et al. (2020) · medRxiv · doi:10.1101/2020.07.18.20155374 · Cited by 143
Self-citationQuinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020) · doi:10.1101/2020.04.10.036418 · Cited by 140
Chan, K. H., Cheng, V. C., Woo, P. C. Y., Lau, S. K. P., Poon, L. L. M., Guan, Y., Seto, W., Yuen, K., & Peiris, M. J. S. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.11.1317-1321.2005 · Cited by 113
He, Y., Zhu, Q., Liu, S., Zhou, Y., Baoan, Y., Li, J., & Jiang, S. (2005) · Virology · doi:10.1016/j.virol.2005.01.034 · Cited by 100
Secchi, M., Bazzigaluppi, E., Brigatti, C., Marzinotto, I., Tresoldi, C., Rovere, P. Q., Poli, A., Castagna, A., Scarlatti, G., Zangrillo, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142804 · Cited by 94
SARS-CoV-2-specific ELISA development
Roy, V., Fischinger, S., Atyeo, C. G., Slein, M. D., Loos, C., Balazs, A. B., Luedemann, C., Astudillo, M. G., Yang, D., Wesemann, D. R., et al. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112832 · Cited by 87
Self-citationStructural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., Marco, A. D., et al. (2020) · Worldwide Protein Data Bank · doi:10.2210/pdb6ws6/pdb · Cited by 82
Yang, R., Huang, B., A, R., Li, W., Wang, W., Deng, Y., & Tan, W. (2020) · Biosafety and Health · doi:10.1016/j.bsheal.2020.08.004 · Cited by 70
Affordable Luciferase Reporter Assay for Cell-Based High-Throughput Screening
Olst, E. S., Vermeulen, C., de Menezes, R. X., Howell, M. T., Smit, E. F., & van Beusechem, V. W. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112465184 · Cited by 57
The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells
Yousif, A. S., Ronsard, L., Shah, P., Omatsu, T., Sangesland, M., Moreno, T. B., Lam, E. C., Vrbanac, V. D., Balazs, A. B., Reinecker, H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.12.001 · Cited by 56
Self-citationA New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, ChinaPreprint
Zhou, Y., Yang, Z. Y., Guo, Y., Geng, S., Gao, S., Ye, S., Hu, Y., & Wang, Y. (2020) · doi:10.21203/rs.3.rs-29566/v1 · Cited by 53
Corver, J., Broer, R., van Kasteren, P. B., & Spaan, W. J. M. (2009) · Virology Journal · doi:10.1186/1743-422x-6-230 · Cited by 50
Inactivation of West Nile Virus during Serologic Testing and Transport
Mayo, D. R., & Beckwith, W. H. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.8.3044-3046.2002 · Cited by 29
Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis
Ullah, W., Abdullah, H. M. A., Roomi, S., Sattar, Y., Almas, T., Gowda, S. N., Saeed, R., Mukhtar, M., Ahmad, A., Oliver, T., et al. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4233 · Cited by 12
Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus
Santos, I. K. F. D. M., & Costa, C. H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01739 · Cited by 12
Sarkar, S., Piepenbrink, M. S., Basu, M., Thakar, J., Keefer, M. C., Hessell, A. J., Haigwood, N. L., & Kobie, J. J. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.03.044 · Cited by 9
Research works printed but not linked: 4
- Du, 2010, Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies, Biochem. Biophys. Res. Commun., 397, 580, 10.1016/j.bbrc.2010.05.161 · doi:10.1016/j.bbrc.2010.05.161
- Mulligan, 2020, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, Nature, 586, 589, 10.1038/s41586-020-2639-4 · doi:10.1038/s41586-020-2639-4 · Paper page
- Ujike, 2016, The contribution of the cytoplasmic retrieval signal of severe acute respiratory syndrome coronavirus to intracellular accumulation of S proteins and incorporation of S protein into virus-like particles, J. Gen. Virol., 97, 1853, 10.1099/jgv.0.000494 · doi:10.1099/jgv.0.000494
- Zhou, 2020, SARS-CoV-2 Spike D614G Variant Confers Enhanced Replication and Transmissibility, bioRxiv
Cited by
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Self-citationThe biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045
Self-citationDiverse functional autoantibodies in patients with COVID-19
Wang, E. Y., Mao, T., Klein, J., Dai, Y., Huck, J. D., Jaycox, J. R., Liu, F., Zhou, T., Israelow, B., Wong, P., et al. (2021) · Nature · doi:10.1038/s41586-021-03631-y · Cited by 992
FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
Junqueira, C., Crespo, Â., Ranjbar, S., de Lacerda, L. B., Lewandrowski, M., Ingber, J., Parry, B., Ravid, S., Clark, S., Schrimpf, M. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04702-4 · Cited by 631
Metadata
- Authors
- Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J., Hauser, B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., Murali, M. R., Alter, G., Charles, R. C., Dighe, A., Branda, J. A., Lennerz, J. K., Lingwood, D., Schmidt, A. G., Iafrate, A. J., & Balazs, A. B.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 184
- Issue
- 2
- Pages
- 476-488.e11
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W3113228067
- Cited by
- 722
- References
- 78
- FWCI
- 17.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 385 d)
- Funders
- Massachusetts General Hospital
- Charles H. Hood Foundation
- Gilead Sciences
- National Institutes of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.